Lentiviral Vector Patents: Who Leads, Where the Gaps Are 2026
Lentiviral vector manufacturing patents: leaders, filing trends and open claim space
Filings peaked in 2021 at 436 and fell 47% to 231 by 2024, the last year the dataset treats as complete — a real pullback in new filing, not a data artefact. Filings ran from 261 in 2017 to a peak of 436 in 2021, then declined to 231 by 2024 — a 47% drop over that three-year span. Years after 2024 are still incomplete because of publication lag and should not be read against this figure.
- 1CITY OF HOPE4.2%
- 2INST PASTEUR4.0%
- 3FLAGSHIP PIONEERING INNOVATIONS VI LLC4.0%
- 4THERAVECTYS3.2%
- 5GENZYME CORP3.1%
See the full lentiviral vector manufacturing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Frequently asked questions
Who holds the most lentiviral vector manufacturing patents?
The dataset’s assignee ranking shows one clear leader with 217 records, followed by a fifth-placed entrant at 161 and a tenth-placed entrant at 105. The gap from first to tenth is real but not extreme, meaning no single organisation controls the field outright. The top 10 combined hold 29.8% of all 5,157 records in scope, leaving the majority spread across a long tail of smaller filers.
Is lentiviral vector manufacturing patent filing still growing?
No — filings peaked in 2021 at 436 and had fallen to 231 by 2024, a 47% decline over that span, and 2024 is the most recent year the dataset treats as complete. Figures for 2025 and 2026 are still filling in because publication typically lags filing by around 18 months, so they should not yet be read as confirming or reversing that trend. The honest read is a real pullback from a 2021 peak, not a field in early growth.
What are the most heavily claimed technical areas in lentiviral vector manufacturing?
Vector construction and genetic engineering (IPC class C12N) appear on 79.7% of the 5,157 records in scope, and medicinal preparation claims (A61K) appear on 64.3%. Peptide and protein chemistry (C07K) and therapeutic activity claims (A61P) follow at 40.6% and 25.9% respectively. Process-control classes tied to enzymatic testing, fermentation and microorganism indexing each sit under 6%, which is where manufacturing-process detail is comparatively under-claimed relative to the core construct and formulation space.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Lentiviral Vector Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.